The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2019

Filed:

Jul. 08, 2015
Applicants:

The Texas A&m University System, College Station, TX (US);

Temple Therapeutics, Inc., Framingham, MA (US);

Darwin J. Prockop, Philadelphia, PA (US);

Fei Liu, Belton, TX (US);

Qingguo Zhao, Temple, TX (US);

Barry A. Berkowitz, Framingham, MA (US);

Inventors:

Darwin J. Prockop, Philadelphia, PA (US);

Fei Liu, Belton, TX (US);

Qingguo Zhao, Temple, TX (US);

Barry A. Berkowitz, Framingham, MA (US);

Assignees:

The Texas A&M University System, College Station, TX (US);

Temple Therapeutics, Inc., Framingham, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/28 (2015.01); C12N 5/0775 (2010.01);
U.S. Cl.
CPC ...
C12N 5/0668 (2013.01); A61K 35/28 (2013.01); C12N 2501/15 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2506/45 (2013.01);
Abstract

A method of producing mesenchymal stem cells from induced pluripotent stem cells in which induced pluripotent stem cells are cultured in the presence of a TGF-β inhibitor an in an atmosphere containing from about 7 vol. % to about 8 vol. % COfor a period of time from about 20 day to about 35 days. The cells then are transferred to a culture dish having a hydrophilic surface, and the cells are cultured in a medium containing a TGF-β inhibitor for a period of time sufficient to produce mesenchymal stem cells. Such mesenchymal stem cells are more stable and less likely to form tumors, cancers, or teratomas. Also, the induced pluripotent stem cells may be genetically engineered with at least one polynucleotide encoding a therapeutic agent and then are cultured as hereinabove described to provide genetically engineered mesenchymal stem cells that express sustained amounts of a biologically active protein or polypeptide.


Find Patent Forward Citations

Loading…